DEF: Elevation Oncology Seeks Stockholder Approval for Reverse Stock Split to Regain Nasdaq Compliance

Elevation Oncology is asking stockholders to approve a reverse stock split to boost its share price and maintain its Nasdaq listing.

Summary

• Elevation Oncology is holding its 2025 Annual Meeting of Stockholders virtually on June 5, 2025.
• The meeting will address the election of three Class I directors, ratification of the appointment of CohnReznick LLP as the independent registered public accounting firm, and a proposal to approve an amendment to the company's Restated Certificate of Incorporation to effect a reverse stock split.
• The reverse stock split would be at a ratio ranging from 1-for-10 to 1-for-50, with the exact ratio to be determined by the Board of Directors.
• The company is seeking the reverse stock split to regain compliance with Nasdaq's minimum bid price requirement of $1.00 per share.
• As of April 7, 2025, Elevation Oncology had 59,223,728 shares of common stock outstanding.
• The Board of Directors recommends voting in favor of all proposals.

Sentiment

Score: 5

Explanation: The document is neutral in tone, primarily conveying information about the upcoming annual meeting and proposals. The reverse stock split is presented as a necessary measure to maintain Nasdaq compliance, but the document also acknowledges the risks associated with it.

Positives

• Continued listing on Nasdaq could maintain overall credibility to an investment in the company's stock.
• A higher stock price, which may be achieved through a Reverse Stock Split, could encourage investor interest and improve the marketability of the company's common stock to a broader range of investors and thus enhance liquidity of the company's common stock.
• Continued listing on Nasdaq could maintain visibility of the company's stock among a larger pool of potential investors and could result in higher trading volumes, which could also help facilitate potential financings and business development opportunities.

Negatives

• The effect of the Reverse Stock Split, if any, upon the market price of the company's common stock cannot be accurately predicted.
• There can be no assurance that the price for a share of the company's common stock after the Reverse Stock Split will increase in proportion to the reduction in the number of shares of the company's common stock outstanding immediately prior to the Reverse Stock Split.
• The Reverse Stock Split may be viewed negatively by the market and, consequently, could lead to a decrease in the company's overall market capitalization.
• The Reverse Stock Split will also reduce the total number of outstanding shares of the company's common stock, which may lead to reduced trading and a smaller number of market makers for the company's common stock, particularly if the price per share of the company's common stock does not increase as a result of the Reverse Stock Split.

Risks

• The reverse stock split may not increase the stock price.
• The market price of the common stock will also be based on the company's performance and other factors, some of which are unrelated to the reverse stock split or the number of shares outstanding.
• The reverse stock split may lead to a decrease in the company's overall market capitalization.
• The reverse stock split may decrease the liquidity of the company's common stock.
• The reverse stock split may result in higher transaction costs for transactions in the company's common stock.

Future Outlook

The company aims to regain compliance with Nasdaq's minimum bid price requirement and is seeking stockholder approval for a reverse stock split to achieve this goal.

Industry Context

Reverse stock splits are a common strategy for companies facing delisting from major exchanges due to low share prices. The company is trying to avoid trading on the OTC Bulletin Board or pink sheets.

Comparison to Industry Standards

• Many biotechnology companies facing similar challenges have implemented reverse stock splits to maintain their listing on exchanges like Nasdaq.
• Comparable companies that have recently undertaken reverse stock splits include [hypothetical company A] and [hypothetical company B], both of which were seeking to regain compliance with Nasdaq's minimum bid price rule.
• The success of a reverse stock split in increasing and sustaining a company's share price varies depending on the company's underlying fundamentals and market conditions.

Management Changes

Stakeholder Impact

• Shareholders: Potential impact on share price and value of investment.
• Employees: Potential impact on stock-based compensation and company stability.
• Investors: Continued listing on Nasdaq could maintain overall credibility to an investment in the company's stock.

Next Steps

• Stockholder vote on the proposals at the Annual Meeting on June 5, 2025.
• Board of Directors' decision on whether to implement the reverse stock split and, if so, the specific ratio.
• Filing of the Certificate of Amendment with the Secretary of State of Delaware if the reverse stock split is approved and implemented.

Key Dates

Keywords

reverse stock split, proxy statement, annual meeting, Nasdaq, directors, CohnReznick, stockholders, Elevation Oncology, compliance